Salmefamol orally in asthmatics - two doses compared.
The responses of twelve patients with chronic asthma to salmefamol 1 mg and 2 mg, taken orally, were compared in a double-blind cross-over study. Both produced a rise of 40-50% in PEFR and FEV1. Statistically significant improvements were maintained for three to four hours, and 20% improvements for four to six hours. There was no significantly different effect on ventilatory capacity between the two doses. After the 2 mg dose there was a statistically significant fall in diastolic blood pressure at 1 and 1 1/2 hours. Four patients experienced tremor and this was the only side-effect noted. The possible reasons for failure to demonstrate a greater effect with the higher dose are discussed.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D005541:Forced Expiratory Volume; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D010366:Peak Expiratory Flow Rate; D013997:Time Factors; D014797:Vital Capacity
D007545:Isoproterenol